Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fanolyte (often spelled Fanolite) is an oral rehydration solution (ORS) developed and marketed by Bioprojet. It is specifically formulated for the nutritional management of dehydration in infants and young children suffering from acute diarrhea or vomiting. The solution contains a balanced concentration of glucose and electrolytes, including sodium chloride, potassium citrate, and citric acid. Its mechanism of action relies on the sodium-glucose cotransport system (SGLT1) in the intestinal epithelium; the presence of glucose facilitates the active transport of sodium, which in turn creates an osmotic gradient that promotes the absorption of water. This process remains functional even during most types of secretory diarrhea, making Fanolyte an effective therapy for restoring fluid and electrolyte balance and preventing severe dehydration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oral rehydration salts (Bioprojet).